Ulrik H Mistarz1, Susheel K Singh2,3,4, Tam T T N Nguyen1, Will Roeffen5, Fen Yang1, Casper Lissau1, Søren M Madsen6, Astrid Vrang6, Régis W Tiendrebeogo2,3,4, Ikhlaq H Kana2,3,4, Robert W Sauerwein5, Michael Theisen7,8,9, Kasper D Rand10. 1. Department of Pharmacy, University of Copenhagen, Universitetsparken 2, Copenhagen, Denmark. 2. Department for Congenital Disorders, Statens Serum Institut, Artillerivej 5, Copenhagen, Denmark. 3. Centre for Medical Parasitology, University of Copenhagen, Copenhagen, Denmark. 4. Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. 5. Department of Medical Microbiology, Radboud University Nijmegen Medical Center, Nijmegen, The Netherlands. 6. Bioneer A/S, Hørsholm, Denmark. 7. Department for Congenital Disorders, Statens Serum Institut, Artillerivej 5, Copenhagen, Denmark. mth@ssi.dk. 8. Centre for Medical Parasitology, University of Copenhagen, Copenhagen, Denmark. mth@ssi.dk. 9. Department of Infectious Diseases, Copenhagen University Hospital, Rigshospitalet, Copenhagen, Denmark. mth@ssi.dk. 10. Department of Pharmacy, University of Copenhagen, Universitetsparken 2, Copenhagen, Denmark. kasper.rand@sund.ku.dk.
Abstract
PURPOSE: Production and characterization of a chimeric fusion protein (GMZ2'.10C) which combines epitopes of key malaria parasite antigens: glutamate-rich protein (GLURP), merozoite surface protein 3 (MSP3), and the highly disulphide bonded Pfs48/45 (10C). GMZ2'.10C is a potential candidate for a multi-stage malaria vaccine that targets both transmission and asexual life-cycle stages of the parasite. METHODS: GMZ2'.10C was produced in Lactococcus lactis and purified using either an immunoaffinity purification (IP) or a conventional purification (CP) method. Protein purity and stability was analysed by RP-HPLC, SEC-HPLC, 2-site ELISA, gel-electrophoresis and Western blotting. Structural characterization (mass analysis, peptide mapping and cysteine connectivity mapping) was performed by LC-MS/MS. RESULTS: CP-GMZ2'.10C resulted in similar purity, yield, structure and stability as compared to IP-GMZ2'.10C. CP-GMZ2'.10C and IP-GMZ2'.10C both elicited a high titer of transmission blocking (TB) antibodies in rodents. The intricate disulphide-bond connectivity of C-terminus Pfs48/45 was analysed by tandem mass spectrometry and was established for GMZ2'.10C and two reference fusion proteins encompassing similar parts of Pfs48/45. CONCLUSION: GMZ2'.10C, combining GMZ2' and correctly-folded Pfs48/45 can be produced by the Lactoccus lactis P170 based expression system in purity and quality for pharmaceutical development and elicit high level of TB antibodies. The cysteine connectivity for the 10C region of Pfs48/45 was revealed experimentally, providing an important guideline for employing the Pfs48/45 antigen in vaccine design.
PURPOSE: Production and characterization of a chimeric fusion protein (GMZ2'.10C) which combines epitopes of key malaria parasite antigens: glutamate-rich protein (GLURP), merozoite surface protein 3 (MSP3), and the highly disulphide bonded Pfs48/45 (10C). GMZ2'.10C is a potential candidate for a multi-stage malaria vaccine that targets both transmission and asexual life-cycle stages of the parasite. METHODS: GMZ2'.10C was produced in Lactococcus lactis and purified using either an immunoaffinity purification (IP) or a conventional purification (CP) method. Protein purity and stability was analysed by RP-HPLC, SEC-HPLC, 2-site ELISA, gel-electrophoresis and Western blotting. Structural characterization (mass analysis, peptide mapping and cysteine connectivity mapping) was performed by LC-MS/MS. RESULTS: CP-GMZ2'.10C resulted in similar purity, yield, structure and stability as compared to IP-GMZ2'.10C. CP-GMZ2'.10C and IP-GMZ2'.10C both elicited a high titer of transmission blocking (TB) antibodies in rodents. The intricate disulphide-bond connectivity of C-terminus Pfs48/45 was analysed by tandem mass spectrometry and was established for GMZ2'.10C and two reference fusion proteins encompassing similar parts of Pfs48/45. CONCLUSION: GMZ2'.10C, combining GMZ2' and correctly-folded Pfs48/45 can be produced by the Lactoccus lactis P170 based expression system in purity and quality for pharmaceutical development and elicit high level of TB antibodies. The cysteine connectivity for the 10C region of Pfs48/45 was revealed experimentally, providing an important guideline for employing the Pfs48/45 antigen in vaccine design.
Entities:
Keywords:
Pfs48/45; disulphide bond mapping; malaria vaccine; mass spectrometry of biopharmaceuticals; production and stability analysis of biopharmaceuticals
Authors: Carla S Jones; Tiffany Luong; Michael Hannon; Miller Tran; James A Gregory; Zhouxin Shen; Steven P Briggs; Stephen P Mayfield Journal: Appl Microbiol Biotechnol Date: 2012-05-18 Impact factor: 4.813
Authors: Sodiomon B Sirima; Benjamin Mordmüller; Paul Milligan; Ulysse Ateba Ngoa; Fred Kironde; Frank Atuguba; Alfred B Tiono; Saadou Issifou; Mark Kaddumukasa; Oscar Bangre; Clare Flach; Michael Christiansen; Peter Bang; Roma Chilengi; Søren Jepsen; Peter G Kremsner; Michael Theisen Journal: Vaccine Date: 2016-07-28 Impact factor: 3.641
Authors: Silvia A Arredondo; Mengli Cai; Yuki Takayama; Nicholas J MacDonald; D Eric Anderson; L Aravind; G Marius Clore; Louis H Miller Journal: Proc Natl Acad Sci U S A Date: 2012-04-09 Impact factor: 11.205
Authors: Nikolay S Outchkourov; Will Roeffen; Anita Kaan; Josephine Jansen; Adrian Luty; Danielle Schuiffel; Geert Jan van Gemert; Marga van de Vegte-Bolmer; Robert W Sauerwein; Hendrik G Stunnenberg Journal: Proc Natl Acad Sci U S A Date: 2008-03-10 Impact factor: 11.205
Authors: Pedro L Alonso; Graham Brown; Myriam Arevalo-Herrera; Fred Binka; Chetan Chitnis; Frank Collins; Ogobara K Doumbo; Brian Greenwood; B Fenton Hall; Myron M Levine; Kamini Mendis; Robert D Newman; Christopher V Plowe; Mario Henry Rodríguez; Robert Sinden; Laurence Slutsker; Marcel Tanner Journal: PLoS Med Date: 2011-01-25 Impact factor: 11.069
Authors: S Bhatt; D J Weiss; E Cameron; D Bisanzio; B Mappin; U Dalrymple; K Battle; C L Moyes; A Henry; P A Eckhoff; E A Wenger; O Briët; M A Penny; T A Smith; A Bennett; J Yukich; T P Eisele; J T Griffin; C A Fergus; M Lynch; F Lindgren; J M Cohen; C L J Murray; D L Smith; S I Hay; R E Cibulskis; P W Gething Journal: Nature Date: 2015-09-16 Impact factor: 49.962
Authors: Matthias F Muellenbeck; Beatrix Ueberheide; Borko Amulic; Alexandra Epp; David Fenyo; Christian E Busse; Meral Esen; Michael Theisen; Benjamin Mordmüller; Hedda Wardemann Journal: J Exp Med Date: 2013-01-14 Impact factor: 14.307
Authors: Frankie M T Lyons; Mikha Gabriela; Wai-Hong Tham; Melanie H Dietrich Journal: Front Cell Infect Microbiol Date: 2022-07-08 Impact factor: 6.073